ABIVAX Société Anonyme, a biotechnology company, develops, markets, and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases in Asia and Latin America.
The last earnings update was 38 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
ABIVAX Société Anonyme. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
ABIVAX Société Anonyme's
is considered below, and whether this is a fair price.
Price based on past earnings
ABIVAX Société Anonyme's earnings available for a low price, and how does
this compare to other companies in the same industry?
ABIVAX Société Anonyme's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
ABIVAX Société Anonyme's revenue is expected to grow by 9.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
ABIVAX Société Anonyme's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
ABIVAX Société Anonyme
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
ABIVAX Société Anonyme's finances.
The net worth of a company is the difference between its assets and liabilities.
ABIVAX Société Anonyme is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
ABIVAX Société Anonyme's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
ABIVAX Société Anonyme's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
ABIVAX Société Anonyme has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Prof. Dr. Hartmut J. Ehrlich, M.D. has been the Chief Executive Officer of ABIVAX S.A. since December 04, 2013. Prof. Dr. Ehrlich is a physician and global leader with 30 years in academia and in the biopharmaceutical industry, 20 of which were in product development at Baxter and Sandoz (now Novartis). He worked in the United States (Eli Lilly and Indiana University, Dept. of Medicine), the Netherlands (Central Laboratory of the Dutch Red Cross), Germany (Max Planck Foundation, Sandoz, Baxter), Switzerland (Sandoz), Austria (Baxter) and France (ABIVAX). Over the past 7 years before joining ABIVAX, he successfully built and advanced Baxter BioScience’s R&D portfolio with over 50 programs in preclinical and clinical development. He drove the regulatory approval of key biologics in the specialty areas of Hemophilia, Thrombosis, Immunology, Neurology, Oncology, BioSurgery and Vaccines. Prof. Dr. Ehrlich has authored and co-authored over 120 peer-reviewed articles and book chapters. In 2011, Prof. Dr. Ehrlich was named “Professor” by the Austrian President and the Austrian Minister for Science and Research and he received the title of “Adjunct Professor” of the Danube University Krems, Lower Austria in 2013.
Hartmut's compensation has increased whilst company is loss making.
Hartmut's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
ABIVAX Société Anonyme
management team in years:
The tenure for the ABIVAX Société Anonyme management team is about average.
Founder & Chairman
Chief Executive Officer
VP, CFO & Board Secretary
Investor Relations Manager
Human Resources Manager
VP, Chief Commercial Officer & VP of Business Development
VP & Chief Medical Officer
VP & Head of Regulatory Affairs
Board of Directors Tenure
Average tenure and age of the
ABIVAX Société Anonyme
board of directors in years:
The tenure for the ABIVAX Société Anonyme board of directors is about average.
ABIVAX Société Anonyme, a biotechnology company, develops, markets, and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases in Asia and Latin America. Its principal products include ABX 464 that is in Phase II clinical trials for providing a sustained viral remission or functional cure for patients with HIV/AIDS; ABX 203, a therapeutic vaccine candidate, which is in Phase IIb/III clinical trials for the treatment of chronic hepatitis B; and ABX 196, an art immune enhancer candidate that has completed Phase I clinical trials for iNKT cells. It also develops vaccines for typhoid, meningitis B and C, and leptospirosis. In addition, the company’s pre-clinical programs comprise ABX 220 for the treatment of Dengue fever; ABX 544, a drug candidate for the treatment of Ebola based on polyclonal antibodies; and ABX 311 for the treatment of Chikungunya. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier 2 Science and Technology, and the Curie Institute; and a partnership with the Cuban Centro de Ingeneria Genetica y de Biotecnologia. The company was incorporated in 2013 and is headquartered in Paris, France.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.